182 related articles for article (PubMed ID: 7628986)
1. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa.
Chen HY; Yuan M; Ibrahim-Elmagboul IB; Livermore DM
J Antimicrob Chemother; 1995 Apr; 35(4):521-34. PubMed ID: 7628986
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
Eagye KJ; Banevicius MA; Nicolau DP
Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States.
Friedland I; Gallagher G; King T; Woods GL
J Chemother; 2004 Oct; 16(5):437-41. PubMed ID: 15565908
[TBL] [Abstract][Full Text] [Related]
4. National survey of antibiotic resistance in Pseudomonas aeruginosa.
Williams RJ; Lindridge MA; Said AA; Livermore DM; Williams JD
J Antimicrob Chemother; 1984 Jul; 14(1):9-16. PubMed ID: 6434505
[TBL] [Abstract][Full Text] [Related]
5. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
[TBL] [Abstract][Full Text] [Related]
6. Quality of antimicrobial susceptibility testing in the UK: a Pseudomonas aeruginosa survey revisited.
Livermore DM; Chen HY
J Antimicrob Chemother; 1999 Apr; 43(4):517-22. PubMed ID: 10350381
[TBL] [Abstract][Full Text] [Related]
7. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections.
Van Eldere J
J Antimicrob Chemother; 2003 Feb; 51(2):347-52. PubMed ID: 12562701
[TBL] [Abstract][Full Text] [Related]
8. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials.
Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():143-7. PubMed ID: 2509412
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
11. Role of efflux pump inhibitor in decreasing antibiotic cross-resistance of Pseudomonas aeruginosa in a burn hospital in Iran.
Talebi-Taher M; Majidpour َ; Gholami A; Rasouli-Kouhi S; Adabi M
J Infect Dev Ctries; 2016 Jun; 10(6):600-4. PubMed ID: 27367008
[TBL] [Abstract][Full Text] [Related]
12. Widespread detection of VEB-1-type extended-spectrum beta-lactamases among nosocomial ceftazidime-resistant Pseudomonas aeruginosa isolates in Sofia, Bulgaria.
Strateva T; Ouzounova-Raykova V; Markova B; Todorova A; Marteva-Proevska Y; Mitov I
J Chemother; 2007 Apr; 19(2):140-5. PubMed ID: 17434821
[TBL] [Abstract][Full Text] [Related]
13. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
Yetkin G; Otlu B; Cicek A; Kuzucu C; Durmaz R
Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of carbapenem-resistant Pseudomonas aeruginosa strains in patients with ventilator-associated pneumonia in intensive care units.
Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Bakšytė G; Macas A; Sakalauskas R
Medicina (Kaunas); 2011; 47(12):652-6. PubMed ID: 22370463
[TBL] [Abstract][Full Text] [Related]
15. Relation between the antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa from respiratory specimens and antimicrobial use density (AUD) from 2005 through 2008.
Fukushima Y; Fukushima F; Kamiya K; Hayashi Y; Tatewaki M; Yamada I; Hirata H; Sugiyama K; Ishii Y; Fukuda T
Intern Med; 2010; 49(14):1333-40. PubMed ID: 20647645
[TBL] [Abstract][Full Text] [Related]
16. [Susceptibility of Pseudomonas aeruginosa isolated from hospital infections to antibiotics].
Gniadkowski M; Skoczyńska A; Fiett J; Trzciński K; Hryniewicz W
Pol Merkur Lekarski; 1998 Dec; 5(30):346-50. PubMed ID: 10101521
[TBL] [Abstract][Full Text] [Related]
17. Comparison of susceptibility to beta-lactam antimicrobial agents among bacteria isolated from intensive care units.
Pierson CL; Friedman BA
Diagn Microbiol Infect Dis; 1992 Feb; 15(2 Suppl):19S-30S. PubMed ID: 1737439
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993.
Chen HY; Yuan M; Livermore DM
J Med Microbiol; 1995 Oct; 43(4):300-9. PubMed ID: 7562993
[TBL] [Abstract][Full Text] [Related]
19. In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.
Sutherland CA; Verastegui JE; Nicolau DP
Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):39. PubMed ID: 27316973
[TBL] [Abstract][Full Text] [Related]
20. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
Sader HS; Huband MD; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
[No Abstract] [Full Text] [Related]
[Next] [New Search]
